Breaking News, Collaborations & Alliances

Mylan Gains License to Gilead HIV/AIDS Products 


Mylan's Matrix Laboratories Ltd. entered an expanded licensing agreement with Gilead Sciences for the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, currently in late-stage development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mylan’s Matrix Laboratories Ltd. entered an expanded licensing agreement with Gilead Sciences for the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, currently in late-stage development. They include: Elvitegravir, an investigational integrase inhibitor, Cobicistat, an investigational antiretroviral (ARV) boosting agent, and the “Quad,” a once-daily, single-tablet combination of four separate Gilead medicines. Mylan President Heather Bresch sa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters